Floatz logo

Apixaban

Thrombosis

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Thrombosis cohort.

Asset / SponsorPhaseRating
Rivaroxaban
Shanghai Zhongshan Hospital
Phase 4BBB
Acetylsalicylic Acid
China National Center for Cardiovascular Diseases
Phase 4BBB
Dabigatran
St. Antonius Hospital
Phase 4BB
WARFARIN
China National Center for Cardiovascular Diseases
Phase 4BB
Enoxaparin
Helsinki University Central Hospital
Phase 4BB

View all 24 →

Same molecule, other indications

Apixaban is also rated in:

venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
atrial fibrillationDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →